Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Mr. Jerad G. Seurer

General Counsel & Company Secretary

Mr. Gregory J. Davis

Vice President of Corporate and Business Development

Mr. Thomas S. McHugh

Senior Vice President, Principal Financial and Accounting Officer & Chief Financial Officer

Mr. Gregory J. Divis Jr.

Chief Executive Officer & Director

Mr. Richard J. Kim

Chief Commercial Officer

Mr. Mark W. Elrod

Vice President of Sales

Ms. Angie  Woods

Vice President of People & Culture

Dr. Jordan S. Dubow M.D.

Consultant

Dr. Jason M. Vaughn

Senior Vice President of Technical Operations

Ms. Jennifer  Gudeman PharmD

Senior Vice President of Medical & Clinical Affairs

Pavadinimas	Rinkos kapitalizacija
China Medical System Holdings Limited	0M
TILT Holdings Inc.	0M
ZhuZhou QianJin Pharmaceutical Co.,Ltd	0M
Wockhardt Limited	0M
Chong Kun Dang Pharmaceutical Corp.	0.1M
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	0M
Hainan Shuangcheng Pharmaceuticals Co., Ltd.	0M
Eris Lifesciences Limited	0M
Shenzhen Kangtai Biological Products Co., Ltd.	0M
Takeda Pharmaceutical Company Limited	0M
Medical Developments International Limited	0M

Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc Konkurentų sąrašas

Pagrindiniai konkurentai